Ranbaxy: Leveraging on marketing setup - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Ranbaxy: Leveraging on marketing setup

Feb 26, 2002

Ranbaxy has started leveraging on its direct marketing presence in 25 countries across the globe. Yesterday, the company announced entering into an agreement with Penwest, U.S granting Ranbaxy, exclusive marketing rights to market Nifedipine XL, a cardiovascular drug. Ranbaxy would be marketing this drug on behalf of Penwest, USA in key Asian markets such as China, Malaysia, Singapore, Thailand and Sri Lanka. Cumulatively, all these regions have a market close to US$ 50 m for this drug. Though the ultimate revenue occurring to the company at this point of time may be small, it opens new vistas, as it would provide more such opportunities to leverage its marketing set up. Further, it will improve product offerings of the company in its key focus markets besides the US. An improving product basket would improve the bargaining power of the company. UK, Germany, Brazil and China are the other core markets identified by the company.

The speed at which Ranbaxy is cracking export markets is encouraging. The US subsidiaries of the company achieved sales in excess of US$ 113 m. It may be recalled that the company recently got approval for Cefuroxime Axetil in the US markets with expected sales revenues of around US$ 60m. Further, with aggressive product launches, Ranbaxy’s US subsidiaries are likely to cross revenues of US$ 200m in the current financial year.

Considering that most of the identified markets are logging healthy growth rates, the company should continue to log 16-18% CAGR growth over 2005 in exports. The company seems to be ahead of its target in achieving global sales in excess of US$ 1 bn by 2005.


Equitymaster requests your view! Post a comment on "Ranbaxy: Leveraging on marketing setup ". Click here!

  

More Views on News

Sorry! There are no related views on news for this company/sector.

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

MARKET STATS